Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

125.05USD
28 Mar 2017
Change (% chg)

$-0.21 (-0.17%)
Prev Close
$125.26
Open
$124.82
Day's High
$125.55
Day's Low
$124.07
Volume
345,099
Avg. Vol
410,861
52-wk High
$132.95
52-wk Low
$89.74

Latest Key Developments (Source: Significant Developments)

Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare
Tuesday, 27 Sep 2016 07:53am EDT 

Abiomed Inc : Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare . Co planning future discussions with PMDA relating to potential regulatory reviews of Impella CP and Impella RP later this fiscal year . Plans to start supporting patients in Japan during Q4 of FY '17 . Company will conduct a post-market surveillance on Impella usage .Says does not expect material revenue until FY'18.  Full Article

Abiomed reports Q1 gaap earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% . Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S . Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Q1 revenue $103 million versus i/b/e/s view $97.2 million .Is increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million.  Full Article

Abiomed reports Q1 GAAP earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 revenue $103 million versus i/b/e/s view $97.2 million . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Abiomed inc says increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million . Abiomed inc says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc gives FY 2017 revenue guidance
Tuesday, 3 May 2016 07:00am EDT 

Abiomed Inc:Gives FY 2017 guidance for total revenues to be in the range of $430 million to $445 million.  Full Article

Abiomed Inc gives Q3 2016 revenue guidance
Monday, 11 Jan 2016 04:00pm EST 

Abiomed Inc:Says reported preliminary unaudited Q3 2016 revenue of approximately $85.8 million.  Full Article

Abiomed announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements
Monday, 17 Aug 2015 08:00am EDT 

Abiomed Inc:Says that it has submitted U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental submissions requesting to expand Impella 2.5 PMA approval to all of the Impella family of devices (Impella 2.5, Impella CP and Impella 5.0/LD).  Full Article

Abiomed Inc announces corporate partnership with Fenway Park
Tuesday, 11 Aug 2015 01:00pm EDT 

Abiomed Inc:Entered into a corporate partnership with Fenway Park and will be bringing its Impella Mobile Learning Lab to the historic baseball stadium tomorrow.  Full Article

Abiomed Inc raises FY 2016 revenue guidance
Tuesday, 4 Aug 2015 07:00am EDT 

Abiomed Inc:Raises FY 2016 guidance for total revenue to be in the range of $300-$310 million.FY 2016 revenue of $292 million - Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc to appoint New Chief Financial Officer Michael Tomsicek
Monday, 1 Jun 2015 04:15pm EDT 

Abiomed Inc:Robert Bowen, Vice President and Chief Financial Officer since 2008 will retire from Abiomed next month and Michael Tomsicek will be appointed as Vice President and Chief Financial Officer, effective July 15.  Full Article

Abiomed raises FY 2016 revenue guidance
Tuesday, 5 May 2015 07:00am EDT 

Abiomed:Says that it is increasing its FY 2016 guidance for total revenue to be in the range of $285 million to $295 million.  Full Article

More From Around the Web

BRIEF-Abiomed Q3 GAAP earnings per share $0.34

* Abiomed announces Q3 FY 2017 revenue of $114.7 million, up 34% over prior year